NCT03461861View on ClinicalTrials.gov

Network-Level Mechanisms for Preclinical Alzheimer's Disease Development

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

April 11, 2019

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
APOE 4
Interventions
DRUG

AGB101 220 mg

AGB101 oral dose of 220 mg/day capsule, given as once-daily dosing.

OTHER

Placebo

Placebo, oral capsule given once-daily.

Trial Locations (1)

53226

Froedtert & The Medical College of Wisconsin, Milwaukee

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Medical College of Wisconsin

OTHER

NCT03461861 - Network-Level Mechanisms for Preclinical Alzheimer's Disease Development | Biotech Hunter | Biotech Hunter